Epidiolex is not a controlled substance under federal law. The Drug Enforcement Administration removed it from Schedule V of the Controlled Substances Act in August 2020, and the Epidiolex schedule status has been “non-controlled” ever since.1Federal Register. Implementation of the Agriculture Improvement Act of 2018 It is prescribed, filled, and refilled like any other non-scheduled prescription medication.
Epidiolex is an oral solution of purified cannabidiol (CBD), FDA-approved for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients one year of age and older. It remains the only FDA-approved drug product containing a purified substance derived from the cannabis plant.2U.S. Food and Drug Administration. EPIDIOLEX (cannabidiol) Oral Solution Prescribing Information
From Schedule V to Non-Controlled
When the FDA approved Epidiolex in June 2018, federal law required the DEA to schedule any new drug product derived from a Schedule I substance, and cannabis was Schedule I. In September 2018, the DEA placed Epidiolex in Schedule V, the least restrictive controlled substance category. That placement covered only FDA-approved CBD formulations with no more than 0.1 percent residual THC.3Drug Enforcement Administration. FDA-Approved Drug Epidiolex Placed in Schedule V of Controlled Substance Act4Federal Register. Schedules of Controlled Substances: Placement in Schedule V of Certain FDA-Approved Drugs Containing Cannabidiol
Then the Agriculture Improvement Act of 2018, the Farm Bill, was signed in December 2018. It defined “hemp” as cannabis with a THC concentration of 0.3 percent or less by dry weight and removed hemp from the definition of marijuana under the Controlled Substances Act. Epidiolex contains CBD derived from cannabis with far less than 0.3 percent THC, so the Farm Bill removed the legal basis for keeping it on any schedule.1Federal Register. Implementation of the Agriculture Improvement Act of 2018
The DEA formalized the change in an interim final rule published August 21, 2020, removing FDA-approved CBD drug products from Schedule V entirely.1Federal Register. Implementation of the Agriculture Improvement Act of 2018
What Descheduling Means at the Pharmacy
The change shows up every time a prescription is written or filled. While Epidiolex sat in Schedule V, federal rules capped prescriptions at five refills within six months of the original date.5eCFR. 21 CFR Part 1306 – Controlled Substances Listed in Schedules III, IV, and V As a non-controlled drug, Epidiolex can now be prescribed with refills valid for up to a year, matching the standard rules for maintenance medications.
Descheduling also removed several requirements that used to add friction:
- Prescriptions can be transferred between pharmacies more freely, which helps when you move or your usual pharmacy is out of stock.
- Pharmacies no longer need to maintain separate controlled substance inventory records or meet DEA security standards specifically for Epidiolex.
- Prescribers no longer need to include a DEA registration number on the prescription, and the prescription does not need to follow the formatting rules that apply to controlled substances.
State prescription drug monitoring programs are a partial exception. PDMPs were originally built to track controlled substances, but a growing number of states have expanded their programs to include certain non-controlled medications. Descheduling removed Epidiolex from mandatory PDMP reporting in most states, though you should confirm your own state’s current requirements rather than assume a blanket exemption.
State Law Can Still Differ
Federal descheduling set the floor. Each state maintains its own controlled substances act, and most have aligned their schedules with the federal change. Some states were slower to update their laws, and a handful maintain broader restrictions on cannabis-derived products regardless of federal scheduling. A pharmacist familiar with local rules is usually the fastest way to confirm how your state treats Epidiolex.
Epidiolex Is Not the Same as Retail CBD
The scheduling change applies only to Epidiolex, not to the CBD oils, gummies, tinctures, and capsules sold in stores and online. Those retail products are not FDA-approved. The FDA’s position is that CBD cannot be legally marketed as a dietary supplement or added to food because it is the active ingredient in an approved drug product. Retail CBD products have not been evaluated for safety, effectiveness, or accurate labeling. Epidiolex went through clinical trials and the full new drug application process, and its scheduling status has no bearing on the legal status of over-the-counter CBD.6U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD)
Traveling With Epidiolex
Inside the United States, Epidiolex carries no more legal risk than any other prescription medication. Keeping the pharmacy label on the bottle and carrying a copy of the prescription is sound practice, though not required by federal transportation rules.
International travel is different. Cannabis laws vary widely between countries, and a purified, FDA-approved, non-controlled CBD product can still cause problems at foreign customs. The manufacturer has stated that it cannot advise on traveling with Epidiolex outside the United States because each country’s laws differ. If you are traveling abroad, contact the embassy or consulate of your destination country well in advance and ask for written confirmation that the medication is permitted.